☆ 4.7 Meeting Abstract

Lerociclib (G1T38), a continuously dosed oral CDK4/6 inhibitor, with fulvestrant in HR+/HER2-advanced breast cancer patients: Updated phase II results and dose selection

ANNALS OF ONCOLOGY (2020)

Get Full Text
Add to Collection

Journal

ANNALS OF ONCOLOGY
Volume 31, Issue -, Pages S380-S380

Publisher

ELSEVIER
DOI: 10.1016/j.annonc.2020.08.436

Keywords

-

Categories

Oncology

Funding

  1. G1 Therapeutics, Inc.

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.